- Home
- KSS vs DYN Comparison
KSS vs DYN Comparison
Compare KSS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- DYN
- Stock Information
- Founded
- KSS 1962
- DYN 1984
- Country
- KSS United States
- DYN United States
- Employees
- KSS N/A
- DYN N/A
- Industry
- KSS Department/Specialty Retail Stores
- DYN Medicinal Chemicals and Botanical Products
- Sector
- KSS Consumer Discretionary
- DYN Health Care
- Exchange
- KSS Nasdaq
- DYN Nasdaq
- Market Cap
- KSS 1.5B
- DYN 1.4B
- IPO Year
- KSS 1992
- DYN 2020
- Fundamental
- Price
- KSS $13.90
- DYN $12.58
- Analyst Decision
- KSS Sell
- DYN Strong Buy
- Analyst Count
- KSS 14
- DYN 15
- Target Price
- KSS $8.54
- DYN $36.00
- AVG Volume (30 Days)
- KSS 6.9M
- DYN 2.9M
- Earning Date
- KSS 09-02-2025
- DYN 07-28-2025
- Dividend Yield
- KSS 3.60%
- DYN N/A
- EPS Growth
- KSS N/A
- DYN N/A
- EPS
- KSS 1.09
- DYN N/A
- Revenue
- KSS $16,072,000,000.00
- DYN N/A
- Revenue This Year
- KSS N/A
- DYN N/A
- Revenue Next Year
- KSS N/A
- DYN N/A
- P/E Ratio
- KSS $12.75
- DYN N/A
- Revenue Growth
- KSS N/A
- DYN N/A
- 52 Week Low
- KSS $6.04
- DYN $6.36
- 52 Week High
- KSS $21.39
- DYN $47.06
- Technical
- Relative Strength Index (RSI)
- KSS 63.05
- DYN 67.54
- Support Level
- KSS $12.96
- DYN $11.65
- Resistance Level
- KSS $14.08
- DYN $12.68
- Average True Range (ATR)
- KSS 0.76
- DYN 0.78
- MACD
- KSS 0.02
- DYN 0.11
- Stochastic Oscillator
- KSS 82.74
- DYN 74.52
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.